ebola
hemorrhag
fever
caus
ebov
one
aggress
zoonos
affect
human
lead
death
within
day
exposur
six
speci
ebov
known
date
name
geograph
region
first
isol
bundibugyo
reston
sudan
forest
formerli
ivoir
ebov
zair
bombali
ebov
sudan
forest
zair
ebov
respons
outbreak
human
wherea
reston
ebov
infect
nonhuman
primat
bombali
viru
recent
discov
bat
fatal
ebov
infect
character
rapid
viral
replic
combin
inadequ
antivir
respons
hallmark
fatal
case
immun
suppress
cell
level
normal
level
cell
activ
delay
antibodi
respons
blood
high
viremia
genom
copiesml
serum
ebov
pathogenesi
start
subvers
innat
adapt
immun
respons
consequ
induct
harm
inflammatori
respons
tissu
necrosi
due
dissemin
infect
ebov
linear
singlestrand
neg
rna
genom
nucleotid
length
compos
seven
gene
code
eight
protein
order
np
encod
nucleoprotein
gp
encod
glycoprotein
l
encod
polymeras
gp
gene
code
two
molecular
form
gener
rna
edit
conserv
multifunct
protein
cofactor
viral
rna
polymeras
complex
along
np
l
protein
activ
start
earli
stage
ebov
infect
also
doublestrand
rnabind
protein
shown
implic
hamper
innat
immun
respons
block
ifnmedi
antivir
activ
multipl
inhibitori
effect
includ
disrupt
pathway
prevent
phosphoryl
inhibit
activ
ifninduc
dsrna
dicerdepend
protein
kinas
r
antibodi
phage
display
technolog
make
possibl
select
artifici
immun
system
human
antibodi
scfv
format
capabl
specif
recogn
antigen
interest
scfv
consist
vh
vl
chain
region
whole
immunoglobulin
ig
smaller
portion
still
retain
bind
properti
parent
ig
format
ideal
genet
manipul
order
obtain
antibodi
construct
potenti
use
diagnost
therapeut
applic
furthermor
scfv
antibodi
express
insid
cell
intrabodi
bind
intracellular
target
antigen
two
main
mechan
underli
efficaci
intrabodi
knockdown
activ
cytosol
antigen
cytosol
intrabodi
divert
antigen
natur
intracellular
compart
scfv
bind
due
extrasign
intracellular
local
intrabodi
use
reveal
function
protein
interf
function
although
possibl
target
intracellular
antigen
give
therapeut
potenti
number
viral
infect
neurolog
diseas
cancer
studi
report
select
phage
display
character
differ
human
scfv
antibodi
bind
activ
form
zair
ebov
abil
scfv
express
cytosol
intrabodi
revers
inhibit
type
ifn
induct
intracellular
express
test
luciferas
report
gene
inhibit
assay
cell
treat
dsrna
order
isol
antibodi
specif
recombin
express
ecoli
purifi
activ
form
approach
base
phage
display
technolog
use
librari
use
divers
clone
introduc
complementarydetermin
region
variabl
heavi
chain
vh
variabl
light
chain
vl
domain
recov
antigenspecif
antibodi
phage
aliquot
antibodi
librari
contain
cfu
phage
use
pan
procedur
describ
elsewher
fig
solubl
scfv
deriv
iptginduc
coloni
screen
elisa
find
specif
protein
e
coli
coloni
correspond
clone
exhibit
od
valu
elisa
higher
grown
subject
dna
extract
sequenc
analysi
sever
clone
ident
nucleotid
sequenc
five
differ
clone
name
identifi
amino
acid
composit
complet
sequenc
vh
vl
domain
shown
fig
along
schemat
represent
scfv
gene
phagemid
cassett
scfv
reactiv
toward
character
elisa
fig
panel
wb
fig
panel
b
use
recombin
antigen
protein
glucos
oxidas
go
antigo
scfv
detect
use
neg
control
reactiv
elisa
confirm
scfv
wb
posit
observ
scfv
react
kda
protein
identifi
recombin
histag
protein
also
detect
antihi
mab
scfv
recogn
antigen
elisa
show
reactiv
denatur
condit
wb
suggest
probabl
recogn
conform
epitop
part
still
reactiv
wb
probabl
recogn
linear
epitop
specif
reactiv
scfv
confirm
observ
react
irrelev
go
antigen
either
elisa
wb
fig
order
use
scfv
ebov
luciferas
report
gene
inhibit
assay
scfv
gene
select
pcr
amplifi
opportun
oligonucleotid
clone
ptarget
vector
express
eukaryot
system
view
cytoplasm
local
necessari
provid
scfv
signal
sequenc
express
specif
cell
compart
transfect
experi
perform
cho
cell
evalu
function
scfv
ptarget
construct
describ
method
construct
abl
express
scfv
expect
molecular
mass
eukaryot
cell
fig
panel
evalu
capabl
scfv
block
activ
cellbas
miniatur
luciferas
report
gene
inhibit
assay
previous
describ
use
assay
measur
capac
express
inhibit
induc
dsrna
treatment
cell
perform
ebov
luciferas
report
gene
inhibit
assay
use
scfv
crucial
exclud
express
irrelev
scfv
could
influenc
induct
either
absenc
presenc
express
end
cell
transfect
pgl
luc
express
plasmid
cotransfect
irrelev
antigo
scfv
express
plasmid
exclud
nonspecif
effect
due
transfect
procedur
cell
cotransfect
parallel
pgl
luc
express
vector
empti
vector
luciferas
signal
emit
case
pgl
luc
antigo
scfv
concurr
express
compar
obtain
posit
control
also
case
ebov
antigo
scfv
simultan
express
measur
signal
compar
obtain
ebov
express
alon
fig
panel
b
result
confirm
induct
affect
neither
transfect
procedur
irrelev
scfv
either
presenc
absenc
express
next
test
scfv
ptarget
construct
dsrna
rigimedi
luciferas
report
gene
inhibit
assay
two
five
scfv
test
show
signific
abil
p
p
respect
subvert
inhibit
product
gener
dsrna
express
contrast
scfv
show
abil
counteract
inhibit
induct
mediat
ebov
cellular
assay
fig
panel
c
verifi
whether
two
differ
scfv
abl
subvert
inhibit
product
target
differ
epitop
perform
competit
elisa
fig
reli
detect
scfvexpress
phage
particl
compet
solubl
nonphagefus
scfv
bind
antigen
immobil
elisa
plate
possibl
detect
solubl
nonphagefus
scfv
use
antitag
flag
ab
tag
also
present
phage
determin
best
scfv
expressingphag
concentr
competit
test
identifi
tuml
first
perform
phage
elisa
experi
differ
scfvexpress
phage
concentr
test
coat
plate
data
shown
competit
assay
elisa
plate
coat
control
antigen
go
block
incub
purifi
scfvexpress
phage
absenc
presenc
competitor
solubl
nonphagefus
scfv
maximum
concentr
bind
scfvexpress
phage
measur
detect
step
via
phage
coat
protein
use
mab
conjug
hrp
antigo
scfvexpress
phage
clone
assay
antigo
solubl
nonphagefus
scfv
posit
control
competit
measur
fig
panel
found
solubl
nonphagefus
scfv
could
inhibit
bind
scfvexpress
phage
dosedepend
manner
bind
presenc
specif
antigo
solubl
nonphagefus
scfv
compar
bind
presenc
solubl
nonphagefus
scfv
p
valu
bind
presenc
solubl
nonphagefus
scfv
p
valu
bind
absenc
solubl
nonphagefus
scfv
p
valu
use
student
ttest
next
assay
bind
scfvexpress
phage
absenc
presenc
competitor
solubl
nonphagefus
scfv
intrins
posit
control
antigo
solubl
nonphagefus
scfv
neg
control
solubl
nonphagefus
scfv
competit
measur
inhibit
activ
determin
singl
fix
concentr
solubl
nonphagefus
scfv
show
clear
competit
effect
concentr
use
fig
panel
b
bind
presenc
solubl
nonphagefus
scfv
compar
bind
presenc
antigo
solubl
nonphagefus
scfv
p
valu
absenc
solubl
nonphagefus
scfv
p
valu
use
student
ttest
confirm
perform
oneshot
experi
detect
competit
suffer
scfvexpress
phage
coincub
solubl
nonphagefus
scfv
control
antigo
solubl
nonphagefus
scfv
concentr
also
case
observ
control
antigo
solubl
nonphagefus
scfv
competit
bind
effect
solubl
nonphagefus
scfv
compet
bind
scfv
expressingphag
bind
presenc
solubl
nonphagefus
scfv
compar
bind
presenc
antigo
solubl
nonphagefus
scfv
p
valu
bind
absenc
solubl
nonphagefus
scfv
p
valu
use
student
ttest
data
shown
urgenc
find
effect
counter
measur
ebov
diseas
evd
strengthen
west
africa
outbreak
occur
result
case
ebola
death
push
intern
scientif
commun
investig
widest
possibl
rang
defens
strategi
counteract
viru
howev
current
ebola
outbreak
start
may
democrat
republ
congo
drc
caus
case
death
date
receiv
minor
benefit
use
new
diagnost
assay
vaccin
drug
reason
control
ebola
outbreak
transvers
coordin
health
facil
commun
essenti
achiev
rapid
isol
case
diseas
stop
transmiss
chain
detect
new
case
earli
stage
rapid
diagnost
test
ring
vaccin
strategi
experiment
vaccin
volunt
therefor
crucial
control
ebov
current
drc
outbreak
due
variabl
onset
antibodi
respons
ebolainfect
subject
serolog
use
acut
evd
diagnosi
convers
viru
viral
protein
accumul
blood
detect
level
within
day
diseas
onset
molecular
test
base
detect
viral
protein
develop
prove
effect
diagnosi
acut
infect
current
case
suspect
ebov
infect
world
health
organ
recommend
list
valid
test
detect
either
viral
rna
rt
pcr
viral
antigen
immunolog
test
http
wwwwhointmedicinesebolatreatmentempeboladiagnosticsen
antigencaptur
test
use
nation
refer
laboratori
util
mab
gener
mice
immun
recombin
np
gp
ebov
protein
recent
outbreak
later
flow
immunoassay
lfi
emerg
power
tool
rapid
antibodymedi
antigencaptur
practic
point
care
confirm
advantag
test
base
antigenantibodi
reaction
rtpcr
methodolog
requir
signific
laboratori
infrastructur
often
lack
lowincom
countri
furthermor
order
control
transmissionchain
infect
limit
viru
spread
import
test
easili
autom
antigen
captur
test
meet
requir
ebov
valid
drug
target
small
molecul
report
activ
albeit
drug
yet
approv
present
mab
scfv
format
abl
react
zair
ebov
protein
key
viral
protein
whose
action
start
earli
stage
infect
base
interfer
host
immun
respons
block
ifnmedi
antivir
activ
antibodi
present
enrich
list
avail
antibodi
could
use
individu
combin
develop
novel
reagent
ebov
detect
therapeut
regard
therapi
pool
neutral
antibodi
use
passiv
immun
individu
acut
infect
nevertheless
antibodi
specif
would
act
differ
mechan
respect
neutral
antibodi
target
surfac
glycoprotein
recent
studi
show
target
either
nucleic
acid
mimic
sirna
provid
protect
ebov
infect
murin
well
nonhuman
primat
model
howev
effect
antibodi
target
yet
demonstr
vivo
show
two
five
scfv
antibodi
select
significantli
hinder
inhibit
rigi
signal
cascad
mediat
cellular
system
character
bind
two
scfv
clone
recombin
antigen
competit
elisa
found
epitop
least
partli
share
detail
analysi
bind
epitop
could
defin
whether
total
partial
share
antigen
region
ebov
involv
inhibit
interferon
pathway
regard
scfv
select
exclud
observ
lack
function
due
incorrect
scfv
fold
cytoplasm
environ
antibodi
usual
produc
oxid
biochem
environ
help
erbas
chaperon
fraction
antibodi
fold
correctli
reduc
cytoplasm
environ
prevent
format
disulfid
bridg
howev
mani
exampl
success
intrabodymedi
protein
knockdown
vitro
obtain
use
cytosol
intrabodi
report
literatur
scfv
select
extracellular
environ
previous
report
work
intracellularli
depend
intrins
biophys
characterist
stabil
mainli
ascrib
scaffold
howev
sever
method
develop
address
issu
cytosol
intrabodi
function
interestingli
scfv
abl
interfer
activ
recent
isol
phage
librari
differ
link
cellpenetr
peptid
intracytoplasm
deliveri
therefor
although
use
differ
deliveri
system
data
strengthen
idea
intracellular
antibodi
scfv
format
use
counteract
ebov
activ
scfv
differ
intracellular
ebov
target
could
use
either
develop
welldefin
cocktail
antibodi
differ
specif
also
combin
drug
molecul
therapeut
purpos
provid
appropri
deliveri
system
develop
furthermor
amino
acid
sequenc
highli
conserv
among
zair
ebov
isol
sever
outbreak
amino
acid
ident
therefor
hypothes
scfv
select
retain
broadspectrum
activ
nevertheless
efficaci
new
antibodi
evalu
either
ebolaviru
infect
cell
anim
model
ebolaviru
infect
five
scfv
antibodi
activ
form
zair
ebov
isol
character
specif
reactiv
elisa
wb
suggest
possibl
develop
novel
reagent
ebov
detect
viru
life
cycl
two
scfv
prove
abl
interfer
inhibit
ifn
activ
cell
system
suggest
antibodi
also
repres
potenti
therapeut
agent
investig
ebov
infect
system
vitro
anim
model
necessari
valid
reagent
synthet
librari
recombin
human
antibodi
consist
scfv
polypeptid
display
surfac
phage
librari
built
random
mutagenesi
complementaritydetermin
region
variabl
domain
heavi
vh
light
vl
chain
immunoglobulin
use
three
antibodi
germlin
gene
segment
vh
vl
vh
divers
creat
random
four
six
posit
replac
preexist
posit
vl
divers
obtain
random
six
posit
aliquot
librari
contain
cfu
phage
use
isol
specif
human
antibodi
scfv
format
recombin
protein
immunotub
nunc
maxisorp
denmark
coat
overnight
room
temperatur
rt
purifi
recombin
protein
pb
pan
phage
elut
ml
mm
triethylamin
solut
immedi
neutral
ad
ml
trishcl
ph
elut
phage
use
infect
e
coli
strain
log
phase
amplifi
next
round
select
describ
flego
et
al
three
round
pan
perform
recov
antibodi
phage
librari
prepar
solubl
scfv
individu
coloni
grown
flat
bottom
well
nunc
h
glucos
medium
induc
mm
medium
follow
day
plate
spun
g
min
supernat
contain
solubl
scfv
recov
test
specif
purifi
elisa
wb
describ
flego
et
al
plasmid
dna
individu
bacteri
coloni
clone
extract
use
quiaprep
spin
miniprep
kit
subject
enzymat
restrict
sequenc
analysi
region
perform
autom
dna
sequenc
biofab
roma
itali
use
ttt
tct
gta
tga
pelbback
cgc
tgg
att
gtt
att
primer
scfv
gene
clone
react
recombin
elisa
pcr
amplifi
use
follow
primer
nco
forward
primer
gcgc
acc
atg
gcc
gag
gtg
cag
ctg
nhe
stop
revers
primer
gcgc
gct
agc
cta
atg
atg
atg
atg
atg
atg
tgc
ggc
cgc
gcc
tag
gac
contain
tag
sequenc
transient
express
eukaryot
cell
amplim
clone
ptarget
promega
strong
viral
promot
cytomegaloviru
immediateearli
enhanc
clone
obtain
sequenc
check
mutat
possibl
introduc
pcr
use
transfect
cho
cell
use
jetpei
dna
transfect
reagent
accord
manufactur
instruct
transient
transfect
cell
lyse
h
sdsload
buffer
mm
trishcl
ph
sd
glycerol
load
onto
sdspage
transfer
nitrocellulos
membran
use
standard
procedur
membran
block
mpb
rt
blot
protein
incub
h
mpb
antibodi
qiagen
antihi
mab
abl
recogn
tag
scfv
cooh
terminu
experiment
condit
addit
incub
h
rt
presenc
goat
antimous
antibodi
hrpconjug
dako
reaction
develop
visual
chemiluminesc
detect
kit
pierc
il
usa
cell
per
well
transfect
plate
tpro
pfect
transfect
reagent
tpro
biotechnolog
construct
pgl
luc
kindli
provid
prof
stephan
ludwig
institut
molecular
virolog
germani
twentyfour
hour
transfect
cell
addit
transfect
use
iav
vrna
incub
h
cell
harvest
lysi
buffer
mm
name
ph
mm
trishcl
ph
mm
dithiothreitol
triton
crude
cell
lysat
clear
centrifug
clear
lysat
ad
luciferas
assay
buffer
mm
name
ph
mm
trishcl
ph
mm
magnesium
acet
mgml
atp
white
plate
immedi
addit
mm
dluciferin
well
luminesc
measur
luminomet
perkin
elmer
rel
light
unit
rlu
normal
fold
activ
unstimul
control
assay
carri
triplic
describ
luciferas
report
gene
assay
also
perform
evalu
induct
inhibit
mediat
ebov
twentyfour
hour
cotransfect
pgl
luc
ebov
express
vector
cell
transfect
ctrl
antigo
scfv
ptarget
irrelev
scfv
differ
scfv
p
target
vector
next
day
cell
addit
transfect
iav
vrna
inhibit
luciferas
express
indic
either
fold
activ
unstimul
control
percentag
induc
control
assay
carri
triplic
elisa
competit
assay
use
solubl
nonphagefus
scfv
produc
purifi
gellini
et
al
scfvexpress
phage
produc
monoclon
bacteri
cultur
grown
infect
helper
phage
ratio
around
phagebacteria
one
hundr
ml
supernat
contain
scfvexpress
phage
concentr
precipit
peg
resuspend
pb
phage
titer
determin
plate
bacteria
infect
phage
scalar
dilut
coat
perform
go
antigen
describ
elisa
section
follow
day
plate
block
mpb
h
rt
wash
tpb
twentyf
solubl
nonphagefus
scfv
twofold
desir
final
concentr
preincub
mpb
antigen
min
prior
addit
scfvexpress
phage
mix
two
time
desir
final
tuml
mpb
incub
h
rt
plate
wash
tpb
incub
pviii
coat
protein
mab
conjug
hrp
amhersham
dilut
h
rt
wash
step
conduct
follow
addit
peroxidas
substrat
describ
